Key Takeaway: Xilio Therapeutics has reported its financial results for the second quarter of 2026, highlighting significant advancements in its pipeline. The company received FDA clearance for its IND application for XTX501, a bispecific PD-1 / masked IL-2 therapy. Additionally, Xilio is progressing with IND-enabling studies for multi-specific T cell engager programs targeting CLDN18.2 and PSMA+STEAP1.
Market Sentiment Analysis
POSITIVE FACTORS
FDA clearance of IND application for XTX501.
Advancing IND-enabling studies for new bispecific programs.
Potential for first-in-class therapies targeting CLDN18.2 and PSMA+STEAP1.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+66%
120-day peak, hindsight
Typical move
21.2%
average across 4 past catalysts
Cash runway
~117 mo
Minimal dilution risk
Lead asset
vilastobart
Phase 1 · Advanced Solid Tumor
Full Press Release Details
Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1; IND applications anticipated in the second
Frequently Asked Questions
What financial results did Xilio report for Q2 2026?
Xilio Therapeutics reported its financial results for the second quarter of 2026.
What is XTX501?
XTX501 is a bispecific PD-1 / masked IL-2 therapy that received FDA IND clearance.
What new programs is Xilio advancing?
Xilio is advancing IND-enabling studies for multi-specific T cell engager programs.
What targets are Xilio's new programs focusing on?